Overview of agents under development for chronic weight loss as of May Download Scientific Diagram Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling MM+M Medical Marketing and Media Eloralintide Lilly's Amylin Agonist Outperforms Novo's Cagrilintide at 48 Weeks BioCentury Can tolerability make petrelintide competitive in obesity? CagriSema achieves >20% weight loss in adults with obesity. Content TribeMD}